Clinical trial
A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors
NCT03074513 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- March 3, 2017
- Completion date
- September 30, 2027
- Enrollment
- 133 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
appendix adenocarcinoma, human papillomavirus-related anal squamous cell carcinoma, human papillomavirus-related cervical squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma of the penis, human papillomavirus-related vulvar squamous cell carcinoma, neuroendocrine carcinoma, pancreatic neuroendocrine tumor, recurrent merkel cell carcinoma, recurrent nasopharynx carcinoma, recurrent peritoneal malignant mesothelioma, recurrent pleural malignant mesothelioma, stage iii merkel cell carcinoma ajcc v7, stage iii nasopharyngeal carcinoma ajcc v7, stage iii pleural malignant mesothelioma ajcc v7, stage iv merkel cell carcinoma ajcc v7, stage iv nasopharyngeal carcinoma ajcc v7, stage iv pleural malignant mesothelioma ajcc v7, stage iva nasopharyngeal carcinoma ajcc v7, stage ivb nasopharyngeal carcinoma ajcc v7, stage ivc nasopharyngeal carcinoma ajcc v7, vaginal squamous cell carcinoma, not otherwise specified